Announcements Trials
Browse Landscape

Phase

Phase 3 37Phase 2 31Phase 1/2 18Phase 1 10Phase 2/3 5Phase EARLY_PHASE1 2Phase 4 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2

Interventions

Magnetic Resonance Spectroscopy 3Specimen Handling 2Papillomavirus Vaccines 2Lenalidomide 2Immune Checkpoint Inhibitors 2Imatinib Mesylate 2Human Papillomavirus Recombinant Vaccine nonavalent 2Diosmin 2Dexamethasone 2venetoclax 1trametinib 1tocilizumab 1sofosbuvir-velpatasvir drug combination 1semaglutide 1ruxolitinib 1rozanolixizumab 1rasburicase 1radium Ra 223 dichloride 1pyrotinib 1pirtobrutinib 1oxycodone-acetaminophen 1obinutuzumab 1nirogacestat 1nilotinib 1ixazomib 1idelalisib 1human papillomavirus vaccine, L1 type 16, 18 1fluciclovine F-18 1darolutamide 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Dexamethasone × 30 days × Clear all
NCT03934684 2026-05-11

Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma

Amgen

Phase 4 Completed
101 enrolled 14 charts
Plasma cell

Multiple Myeloma

NCT03173092 2026-05-04

A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)

Takeda

Phase 4 Terminated
141 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡